Kidney Cancer Clinical Trial
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
Summary
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease
Greater than 18 years of age
A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy
Able to provide written informed consent
Proficient in the English language and self-reports as literate
Must have an active email address or access to a smart device on which text messages can be received
Exclusion Criteria:
Women cannot be breast-feeding
Does not have regular access to the internet
Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist
Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Rochester New York, 14642, United States More Info
How clear is this clinincal trial information?
